Report Detail

Medical Devices & Consumables Global Oncology Biosimilars Sales Market Report 2020 by Manufacturer, Region, Type and Application

  • RnM3847196
  • |
  • 12 December, 2019
  • |
  • Global
  • |
  • 109 Pages
  • |
  • XYZResearch
  • |
  • Medical Devices & Consumables

In this report, our team research the global Oncology Biosimilars market by type, application, region and manufacturer 2014-2020 and forcast 2021-2026. For the region, type and application, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.

Geographically, this report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Oncology Biosimilars for these regions, from 2014 to 2026 (forecast), covering
China
USA
Europe
Japan
Korea
India
Southeast Asia
South America

Global Oncology Biosimilars market competition by top manufacturers/players, with Oncology Biosimilars sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including
Celltrion Inc.
Pfizer Inc.
Biocon
BIOCAD
Apotex Inc.
Dr. Reddy's Laboratories Ltd.
Sandoz International GmbH
Intas Pharmaceuticals Ltd.
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
G-CSF
Hematopoietic Agents
Monoclonal Antibodies
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Oncology Biosimilars for each application, including
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

If you have any special requirements, please let us know and we will offer you the report as you want.


Table of Contents

    1 Executive Summary

    • 1.1 Definition and Specification
    • 1.2 Report Overview
      • 1.2.1 Manufacturers Overview
      • 1.2.2 Regions Overview
      • 1.2.3 Type Overview
      • 1.2.4 Application Overview
    • 1.3 Industrial Chain
      • 1.3.1 Oncology Biosimilars Overall Industrial Chain
      • 1.3.2 Upstream
      • 1.3.3 Downstream
    • 1.4 Industry Situation
      • 1.4.1 Industrial Policy
      • 1.4.2 Product Preference
      • 1.4.3 Economic/Political Environment
    • 1.5 SWOT Analysis

    2 Market Analysis by Types

    • 2.1 Overall Market Performance(Volume)
      • 2.1.1 G-CSF
      • 2.1.2 Hematopoietic Agents
      • 2.1.3 Monoclonal Antibodies
    • 2.2 Overall Market Performance(Value)
      • 2.2.1 G-CSF
      • 2.2.2 Hematopoietic Agents
      • 2.2.3 Monoclonal Antibodies

    3 Product Application Market

    • 3.1 Overall Market Performance (Volume)
      • 3.1.1 Retail Pharmacies
      • 3.1.2 Hospital Pharmacies
      • 3.1.3 Online Pharmacies

    4 Manufacturers Profiles/Analysis

    • 4.1 Celltrion Inc.
      • 4.1.1 Celltrion Inc. Profiles
      • 4.1.2 Celltrion Inc. Product Information
      • 4.1.3 Celltrion Inc. Oncology Biosimilars Sales, Sales Value(Million USD), Price and Gross Profit
      • 4.1.4 Celltrion Inc. SWOT Analysis
    • 4.2 Pfizer Inc.
      • 4.2.1 Pfizer Inc. Profiles
      • 4.2.2 Pfizer Inc. Product Information
      • 4.2.3 Pfizer Inc. Oncology BiosimilarsSales, Sales Value (Million USD), Price and Gross Profit
      • 4.2.4 Pfizer Inc. SWOT Analysis
    • 4.3 Biocon
      • 4.3.1 Biocon Profiles
      • 4.3.2 Biocon Product Information
      • 4.3.3 Biocon Oncology BiosimilarsSales, Sales Value (Million USD), Price and Gross Profit
      • 4.3.4 Biocon SWOT Analysis
    • 4.4 BIOCAD
      • 4.4.1 BIOCAD Profiles
      • 4.4.2 BIOCAD Product Information
      • 4.4.3 BIOCAD Oncology BiosimilarsSales, Sales Value (Million USD), Price and Gross Profit
      • 4.4.4 BIOCAD SWOT Analysis
    • 4.5 Apotex Inc.
      • 4.5.1 Apotex Inc. Profiles
      • 4.5.2 Apotex Inc. Product Information
      • 4.5.3 Apotex Inc. Oncology BiosimilarsSales, Sales Value (Million USD), Price and Gross Profit
      • 4.5.4 Apotex Inc. SWOT Analysis
    • 4.6 Dr. Reddy's Laboratories Ltd.
      • 4.6.1 Dr. Reddy's Laboratories Ltd. Profiles
      • 4.6.2 Dr. Reddy's Laboratories Ltd. Product Information
      • 4.6.3 Dr. Reddy's Laboratories Ltd. Oncology BiosimilarsSales, Sales Value (Million USD), Price and Gross Profit
      • 4.6.4 Dr. Reddy's Laboratories Ltd. SWOT Analysis
    • 4.7 Sandoz International GmbH
      • 4.7.1 Sandoz International GmbH Profiles
      • 4.7.2 Sandoz International GmbH Product Information
      • 4.7.3 Sandoz International GmbH Oncology BiosimilarsSales, Sales Value (Million USD), Price and Gross Profit
      • 4.7.4 Sandoz International GmbH SWOT Analysis
    • 4.8 Intas Pharmaceuticals Ltd.
      • 4.8.1 Intas Pharmaceuticals Ltd. Profiles
      • 4.8.2 Intas Pharmaceuticals Ltd. Product Information
      • 4.8.3 Intas Pharmaceuticals Ltd. Oncology BiosimilarsSales, Sales Value (Million USD), Price and Gross Profit
      • 4.8.4 Intas Pharmaceuticals Ltd. SWOT Analysis
    • 4.9 STADA Arzneimittel AG
      • 4.9.1 STADA Arzneimittel AG Profiles
      • 4.9.2 STADA Arzneimittel AG Product Information
      • 4.9.3 STADA Arzneimittel AG Oncology BiosimilarsSales, Sales Value (Million USD), Price and Gross Profit
      • 4.9.4 STADA Arzneimittel AG SWOT Analysis
    • 4.10 Teva Pharmaceutical Industries Ltd.
      • 4.10.1 Teva Pharmaceutical Industries Ltd. Profiles
      • 4.10.2 Teva Pharmaceutical Industries Ltd. Product Information
      • 4.10.3 Teva Pharmaceutical Industries Ltd. Oncology BiosimilarsSales, Sales Value (Million USD), Price and Gross Profit
      • 4.10.4 Teva Pharmaceutical Industries Ltd. SWOT Analysis

    5 Market Performance for Manufacturers

    • 5.1 Global Oncology Biosimilars Sales (K Units) and Market Share by Manufacturers 2014-2020
    • 5.2 Global Oncology Biosimilars Revenue (M USD) and Market Share by Manufacturers 2014-2020
    • 5.3 Global Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
    • 5.4 Global Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
    • 5.5 Market Concentration

    6 Regions Market Performance for Manufacturers

    • 6.1 China Market Performance for Manufacturers
      • 6.1.1 China Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.1.2 China Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.1.3 China Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.1.4 China Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.1.5 Market Concentration
    • 6.2 USA Market Performance for Manufacturers
      • 6.2.1 USA Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.2.2 USA Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.2.3 USA Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.2.4 USA Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.2.5 Market Concentration
    • 6.3 Europe Market Performance for Manufacturers
      • 6.3.1 Europe Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.3.2 Europe Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.3.3 Europe Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.3.4 Europe Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.3.5 Market Concentration
    • 6.4 Japan Market Performance for Manufacturers
      • 6.4.1 Japan Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.4.2 Japan Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.4.3 Japan Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.4.4 Japan Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.4.5 Market Concentration
    • 6.5 Korea Market Performance for Manufacturers
      • 6.5.1 Korea Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.5.2 Korea Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.5.3 Korea Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.5.4 Korea Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.5.5 Market Concentration
    • 6.6 India Market Performance for Manufacturers
      • 6.6.1 India Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.6.2 India Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.6.3 India Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.6.4 India Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.6.5 Market Concentration
    • 6.7 Southeast Asia Market Performance for Manufacturers
      • 6.7.1 Southeast Asia Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.7.2 Southeast Asia Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.7.3 Southeast Asia Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.7.4 Southeast Asia Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.7.5 Market Concentration
    • 6.8 South America Market Performance for Manufacturers
      • 6.8.1 South America Oncology Biosimilars Sales (K Units) and Share of Manufacturers 2014-2020
      • 6.8.2 South America Oncology Biosimilars Revenue (M USD) and Share of Manufacturers 2014-2020
      • 6.8.3 South America Oncology Biosimilars Price (USD/Unit) of Manufacturers 2014-2020
      • 6.8.4 South America Oncology Biosimilars Gross Margin of Manufacturers 2014-2020
      • 6.8.5 Market Concentration

    7 Global Oncology Biosimilars Market Assessment by Regions (2014-2020)

    • 7.1 Global Oncology Biosimilars Sales (K Units) and Market Share by Regions 2014-2020
    • 7.2 Global Oncology Biosimilars Revenue (M USD) and Market Share by Regions 2014-2020
    • 7.3 Global Oncology Biosimilars Price (USD/Unit) by Regions 2014-2020
    • 7.4 Global Oncology Biosimilars Gross Margin by Regions 2014-2020

    8 Development Trend for Regions

    • 8.1 Global Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.2 China Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.3 USA Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate2014-2020
    • 8.4 Europe Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.5 Japan Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.6 Korea Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.7 India Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.8 Southeast Asia Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020
    • 8.8 Southeast Asia Oncology Biosimilars Sales and Growth, Sales Value and Growth Rate 2014-2020

    9 Upstream Source, Technology and Cost

    • 9.1 Upstream Source
    • 9.2 Technology
    • 9.3 Cost

    10 Channel Analysis

    • 10.1 Market Channel
    • 10.2 Manufacturing Plants Distribution

    11 Consumer Analysis

    • 11.1 Retail Pharmacies Industry
    • 11.2 Hospital Pharmacies Industry
    • 11.3 Online Pharmacies Industry

    12 Market Forecast 2021-2026

    • 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
      • 12.1.1 Global Oncology Biosimilars Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
      • 12.1.2 Global Oncology Biosimilars Sales (K Units) and Growth Rate 2021-2026
      • 12.1.3 China Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.4 USA Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.5 Europe Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.6 Japan Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.7 Korea Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.8 India Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.9 Southeast Asia Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
      • 12.1.10 South America Oncology Biosimilars Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
    • 12.2 Sales (K Units), Revenue (M USD) Forecast by Types 2021-2026
      • 12.2.1 Overall Market Performance
      • 12.2.2 G-CSF
      • 12.2.3 Hematopoietic Agents
      • 12.2.4 Monoclonal Antibodies
    • 12.3 Sales (K Units) Forecast by Application 2021-2026
      • 12.3.1 Overall Market Performance
      • 12.3.2 Retail Pharmacies
      • 12.3.3 Hospital Pharmacies
      • 12.3.4 Online Pharmacies
    • 12.4 Price (USD/Unit) and Gross Profit
      • 12.4.1 Global Oncology Biosimilars Price (USD/Unit) Trend 2021-2026
      • 12.4.2 Global Oncology Biosimilars Gross Profit Trend 2021-2026

    13 Conclusion

    Summary:
    Get latest Market Research Reports on Oncology Biosimilars Sales . Industry analysis & Market Report on Oncology Biosimilars Sales is a syndicated market report, published as Global Oncology Biosimilars Sales Market Report 2020 by Manufacturer, Region, Type and Application. It is complete Research Study and Industry Analysis of Oncology Biosimilars Sales market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,650.00
    $7,200.00
    2,916.35
    5,752.80
    3,387.20
    6,681.60
    568,889.00
    1,122,192.00
    305,030.50
    601,704.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report